Mycosis fungoides

This study tests whether a cream called delgocitinib, already approved for chronic hand eczema, is safe and tolerable when applied to skin affected by early-stage cutaneous T-cell lymphoma (mycosis fungoides). Up to 15 adults with stable disease will apply the cream twice daily f…

This phase II trial tests whether adding lisaftoclax to brentuximab vedotin improves outcomes for people with CD30-positive cutaneous T-cell lymphoma, including mycosis fungoides and primary cutaneous anaplastic large cell lymphoma. About 46 participants are randomly assigned to …

This early-phase trial tests a topical gel containing duvelisib, a drug that blocks certain immune signals, in people with early-stage mycosis fungoides — a type of skin lymphoma. The study enrolls about 30 participants with stage IA to IIA disease who have 3 to 5 accessible skin…

This pilot study tests an oral drug called golidocitinib in people with two rare blood cancers: mycosis fungoides/Sézary syndrome (a type of skin lymphoma) and T-cell large granular lymphocytic leukemia. The drug blocks a protein called JAK1, which is involved in cancer cell grow…

This study tests a cream called benvitimod (tapinarof) for people with cutaneous T-cell lymphoma, a rare skin cancer that causes red patches and itching. The cream is non-steroidal and works by targeting a specific receptor in skin cells. About 35 adults with the disease will app…

This early-stage study tests a wound spray (APR-TD011) on skin lesions caused by cutaneous T cell lymphoma. Researchers want to see if the spray can reduce harmful bacteria (Staphylococcus aureus) on the skin and if it is well tolerated. The study will include 30 adults with earl…

This Phase II trial tests a new drug called VG712 against an existing drug, mogamulizumab, in about 386 people with advanced mycosis fungoides, a rare type of skin lymphoma. VG712 is designed to kill cancerous immune cells by blocking protein production. The study aims to see if …

This early-phase trial tests a new drug called DT-7012 for people with a rare type of skin lymphoma (CTCL) that has not responded to other treatments. The drug is an antibody designed to find and kill cancer cells in the skin and boost the immune system. About 30 adults with adva…

This phase 3 trial tests whether the drug brentuximab vedotin can prevent relapse in people with advanced cutaneous T-cell lymphoma (CTCL) who have recently had a stem cell transplant. About 84 adults with CD30-positive CTCL will receive either the drug or a placebo every three w…

This study asks whether an artificial intelligence algorithm can diagnose mycosis fungoides, a rare type of skin lymphoma, from biopsy slides as accurately as certified dermatopathologists. Researchers will compare the AI's sensitivity and specificity against expert readings usin…